SynthesisHealth technology assessment (Winchester, England)2024

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Nigel Fleeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.